The SA Journal Diabetes & Vascular Disease Volume 18 No 2 (November 2021)

PEARLOC 4 mg/5 mg, 4 mg/10 mg, 8 mg/ 5 mg, 8 mg/10 mg. Each tablet contains 4, 8 mg perindopril tert -butylamine respectively and 5, 10 mg amlodipine respectively. S3 A50/7.1.3/0230, 0231, 0232, 0233. For full prescribing information, refer to the professional information approved by SAHPRA, February 2021. *FDC – Fixed-dose combination. 1) Bahl VK, et al. Management of hypertension with fixed combination of perindopril and amlodipine in daily clinical practice. Results from the STRONG prospective, observational, multicentre study. American Journal of Cardiovascular Drugs 2009(3):135-142. 2) Bertrand ME. Perindopril / Amlodipine combination: an optimal synergy for cardiovascular protection. European Heart Journal supplements 2009 ;11(supplement E):E22-E25. 3) Data on file. PCA784/09/2021. For further product information contact PHARMA DYNAMICS P O Box 30958 Tokai Cape Town 7966 Fax +27 21 701 5898 Email info@pharmadynamics.co.za CUSTOMER CARE LINE 0860 PHARMA (742 762) / +27 21 707 7000 www.pharmadynamics.co.za NEW PERINDOPRIL TERT -BUTYLAMINE / AMLODIPINE 4 mg/5 mg 4 mg/10 mg 8 mg/5 mg 8 mg/10 mg INTRODUCING OUR Perindopril/Amlodipine, an optimal synergy for: • Significant BP reductions 1 • Improved tolerability 1 • Reduction of CV events 2 Pearloc is: • Bioequivalent to the Originator (Perindopril Arginine/Amlodipine) 3 • Cost-effective vs the Originator 3 PERINDOPRIL TERT -BUTYLAMINE/ A MLODIPINE *FDC